Search Results - "Adams, Dylan N."

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs by Sperling, Adam S., Burgess, Michael, Keshishian, Hasmik, Gasser, Jessica A., Bhatt, Shruti, Jan, Max, Słabicki, Mikołaj, Sellar, Rob S., Fink, Emma C., Miller, Peter G., Liddicoat, Brian J., Sievers, Quinlan L., Sharma, Rohan, Adams, Dylan N., Olesinski, Elyse A., Fulciniti, Mariateresa, Udeshi, Namrata D., Kuhn, Eric, Letai, Anthony, Munshi, Nikhil C., Carr, Steven A., Ebert, Benjamin L.

“…Pharmacologic agents that modulate ubiquitin ligase activity to induce protein degradation are a major new class of therapeutic agents, active in a number of…”
Get full text

Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells by Sellar, Rob S, Sperling, Adam S, Słabicki, Mikołaj, Gasser, Jessica A, McConkey, Marie E, Donovan, Katherine A, Mageed, Nada, Adams, Dylan N, Zou, Charles, Miller, Peter G, Dutta, Ravi K, Boettcher, Steffen, Lin, Amy E, Sandoval, Brittany, Quevedo Barrios, Vanessa A, Kovalcik, Veronica, Koeppel, Jonas, Henderson, Elizabeth K, Fink, Emma C, Yang, Lu, Chan, Anthony, Pokharel, Sheela Pangeni, Bergstrom, Erik J, Burt, Rajan, Udeshi, Namrata D, Carr, Steven A, Fischer, Eric S, Chen, Chun-Wei, Ebert, Benjamin L

“…Targeted protein degradation is a rapidly advancing and expanding therapeutic approach. Drugs that degrade GSPT1 via the CRL4CRBN ubiquitin ligase are a new…”
Get full text

Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice by Fink, Emma C, McConkey, Marie, Adams, Dylan N, Haldar, Saurav D, Kennedy, James A, Guirguis, Andrew A, Udeshi, Namrata D, Mani, D R, Chen, Michelle, Liddicoat, Brian, Svinkina, Tanya, Nguyen, Andrew T, Carr, Steven A, Ebert, Benjamin L

“…Thalidomide and its derivatives, lenalidomide and pomalidomide, are clinically effective treatments for multiple myeloma and myelodysplastic syndrome with…”
Get full text

CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice by Fink, Emma C., McConkey, Marie, Adams, Dylan N., Haldar, Saurav D., Kennedy, James A., Guirguis, Andrew A., Udeshi, Namrata D., Mani, D.R., Chen, Michelle, Liddicoat, Brian, Svinkina, Tanya, Nguyen, Andrew T., Carr, Steven A., Ebert, Benjamin L.

“…Thalidomide and its derivatives, lenalidomide and pomalidomide, are clinically effective treatments for multiple myeloma and myelodysplastic syndrome with…”
Get full text